Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.50 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644361 | 0.76 | CYP2A6 (0.77) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL865990 | 0.76 | CYP2A6 (0.77) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL30027002 | 0.74 | CYP2A6 (0.72) | CYP2A6F11AHRNR4A2CMA1 | |
| Hydrochloric Acid SCHEMBL29200223 | 0.74 | CYP2A6 (0.72) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL2473615 | 0.74 | CYP2A6 (0.72) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL31665941 | 0.71 | CYP2A6 (0.68) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL4288341 | 0.71 | CYP2A6 (0.68) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL14748923 | 0.71 | ESR1 (0.36) | AHRTP53CYP3A4TSHRHSD17B10 | |
| SCHEMBL11302716 | 0.71 | CYP2A6 (0.68) | CYP2A6F11AHRNR4A2CMA1 | |
| SCHEMBL11626337 | 0.71 | CYP2A6 (0.68) | CYP2A6F11AHRNR4A2CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4853380-A | REACTING SULFONATED HETEROCYCLIC SULFUR COMPOUNDS WITH DIAMINES OF PLATINUM NITRATE | INTERNATIONAL PHARMACEUTICAL PRODUCTS (US) | 1989-08-01 | — | — | US | claimed |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-10556890-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556890-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10189825-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189825-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180118727-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20150031709-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031709-A1 | Heteroaryl Compounds and Methods of Use Thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| EP-2812324-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013119895-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013119895-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| EP-1501849-B1 | 4\"-DEOXY-4\"-(S)-AMIDO AVERMECTIN DERIVATIVES | MERIAL LTD (GB) | 2012-07-11 | — | — | EP | disclosed |
| WO-2007001076-A1 | SOLID ELECTROLYTIC CAPACITOR AND PRODUCTION METHOD THEREOF | SHOWA DENKO K.K. (JP) | 2007-01-04 | — | — | WO | disclosed |
| EP-1728256-A1 | CROSSLINKED SELF-DOPING TYPE ELECTRICALLY CONDUCTING POLYMER, PRODUCTION PROCESS THEREOF, PRODUCT COATED WITH THE POLYMER AND ELECTRONIC DEVICE | Showa Denko K.K. (JP) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005091309-A1 | CROSSLINKED SELF-DOPING TYPE ELECTRICALLY CONDUCTING POLYMER, PRODUCTION PROCESS THEREOF, PRODUCT COATED WITH THE POLYMER AND ELECTRONIC DEVICE | SHOWA DENKO K.K. (JP) | 2005-09-29 | — | — | WO | disclosed |
| US-4853380-A | REACTING SULFONATED HETEROCYCLIC SULFUR COMPOUNDS WITH DIAMINES OF PLATINUM NITRATE | INTERNATIONAL PHARMACEUTICAL PRODUCTS (US) | 1989-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031709-A1 | Heteroaryl Compounds and Methods of Use Thereof | COMT, GRIN2C, TPMT | CYP2A6 118/4885F11 4811/4885AHR 386/4885 |
| US-20200277286-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GRIN2C, TPMT | CYP2A6 118/4885F11 4811/4885AHR 386/4885 |
| US-10556890-B2 | Heteroaryl compounds and methods of use thereof | COMT, GRIN2C, TPMT | CYP2A6 118/4885F11 4811/4885AHR 386/4885 |
| US-20180118727-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GRIN2C, TPMT | CYP2A6 118/4885F11 4811/4885AHR 386/4885 |
| US-11332462-B2 | Heteroaryl compounds and methods of use thereof | COMT, GRIN2C, TPMT | CYP2A6 118/4885F11 4811/4885AHR 386/4885 |
| US-10189825-B2 | Heteroaryl compounds and methods of use thereof | COMT, GRIN2C, TPMT | CYP2A6 118/4885F11 4811/4885AHR 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.